Biograil manufactures a capsule-based device that utilizes injection molding to deliver biologics directly into the gastrointestinal wall by harnessing the body's peristaltic forces. This technology eliminates the need for mechanical components, providing a non-invasive alternative to injectable pharmaceuticals.
Funding
$7.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many biologic drugs require administration via injection, leading to patient discomfort, inconvenience, and potential compliance issues. This delivery method can also result in variable drug absorption and bioavailability, impacting therapeutic efficacy.
Solution
Biograil is developing BIONDD™, a capsule-based technology for the oral delivery of biologics. The capsule utilizes injection molding to deliver biologics directly into the gastrointestinal wall by harnessing the body's peristaltic forces. This approach aims to transform injectable pharmaceutical products into convenient oral capsules, eliminating the need for needles and improving patient adherence. By directly targeting the GI wall, Biograil's technology seeks to enhance drug absorption and bioavailability compared to traditional oral formulations. The device is designed without mechanical components, offering a non-invasive alternative to injectable biologics.
Target Audience
The primary target audience includes pharmaceutical companies seeking to reformulate their injectable biologics into oral dosage forms, as well as patients who require biologic therapies but prefer a non-invasive route of administration.
Features
- Capsule-based device for oral delivery of biologics
- Injection molding technology for targeted drug delivery to the gastrointestinal wall
- Utilizes peristaltic forces for capsule actuation and drug release
- Needle-free delivery eliminates injection-related discomfort and inconvenience
- Aims to improve drug absorption and bioavailability compared to traditional oral formulations